| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
GlycoMimetics Inc (NASDAQ: GLYC)
GLYC Technical Analysis
4
| As on 9th Jun 2023 GLYC STOCK Price closed @ 1.82 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.92 & Strong Buy for SHORT-TERM with Stoploss of 1.23 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GLYCSTOCK Price
| Open | 1.83 | Change | Price | % |
| High | 1.83 | 1 Day | 0.02 | 1.11 |
| Low | 1.78 | 1 Week | -0.04 | -2.15 |
| Close | 1.82 | 1 Month | 0.45 | 32.85 |
| Volume | 165257 | 1 Year | 0.25 | 15.92 |
| 52 Week High 4.05 | 52 Week Low 0.54 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| GLYC Daily Charts |
GLYC Intraday Charts |
Whats New @ Bazaartrend |
GLYC Free Analysis |
|
|
GLYC Important Levels Intraday
| RESISTANCE | 1.92 |
| RESISTANCE | 1.89 |
| RESISTANCE | 1.87 |
| RESISTANCE | 1.85 |
| SUPPORT | 1.79 |
| SUPPORT | 1.77 |
| SUPPORT | 1.75 |
| SUPPORT | 1.72 |
GLYC Forecast May 2024
| 4th UP Forecast | 2.67 |
| 3rd UP Forecast | 2.4 |
| 2nd UP Forecast | 2.23 |
| 1st UP Forecast | 2.06 |
| 1st DOWN Forecast | 1.58 |
| 2nd DOWN Forecast | 1.41 |
| 3rd DOWN Forecast | 1.24 |
| 4th DOWN Forecast | 0.97 |
GLYC Weekly Forecast
| 4th UP Forecast | 2.21 |
| 3rd UP Forecast | 2.08 |
| 2nd UP Forecast | 2.01 |
| 1st UP Forecast | 1.93 |
| 1st DOWN Forecast | 1.71 |
| 2nd DOWN Forecast | 1.63 |
| 3rd DOWN Forecast | 1.56 |
| 4th DOWN Forecast | 1.43 |
GLYC Forecast2024
| 4th UP Forecast | 8.85 |
| 3rd UP Forecast | 6.6 |
| 2nd UP Forecast | 5.2 |
| 1st UP Forecast | 3.81 |
| 1st DOWN Forecast | -0.17 |
| 2nd DOWN Forecast | -1.56 |
| 3rd DOWN Forecast | -2.96 |
| 4th DOWN Forecast | -5.21 |
GlycoMimetics Inc ( NASDAQ USA Symbol : GLYC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GLYC Business Profile
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland. Address: 9708 Medical Center Drive, Rockville, MD, United States, 20850
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service